Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists

被引：0
|
作者：
Wilberger, Adam [1 ]
Aisner, Dara
Merrick, Daniel T. [2 ]
机构：
[1] Univ Colorado Hosp, Aurora, CO USA
[2] Univ Colorado, Boulder, CO 80309 USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
2118
引用
收藏
页码：756 / 757
页数：2
相关论文
共 50 条
  • [1] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
    Wilberger, Adam
    Aisner, Dara
    Merrick, Daniel T.
    MODERN PATHOLOGY, 2018, 31 : 756 - 757
  • [2] Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
    Sughayer, Maher A.
    Alnaimy, Farah
    Alsughayer, Anas M.
    Qamhia, Naim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 663 - 666
  • [3] PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays
    Klempner, Samuel J.
    Cowden, Eric S.
    Cytryn, Samuel Louis
    Fassan, Matteo
    Kawakami, Hisato
    Shimada, Hideaki
    Tang, Laura H.
    Wagner, Daniel-Christoph
    Yatabe, Yasushi
    Savchenko, Alexander
    Salcius, Jennifer
    Johng, Dorhyun
    Fairchild, Lauren
    Chen, Jing
    Montenegro, Giuliana
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study
    Paliogiannis, Panagiotis
    Lobrano, Renato
    Bella, Michele Angelo
    Fara, Antonella
    Uras, Maria Gabriela
    Pinna, Maria Antonia
    Tedde, Alessandro
    Madonia, Massimo
    Zinellu, Angelo
    Cossu, Antonio
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 69
  • [5] PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays
    Klempner, Samuel J.
    Cowden, Eric S.
    Cytryn, Samuel L.
    Fassan, Matteo
    Kawakami, Hisato
    Shimada, Hideaki
    Tang, Laura H.
    Wagner, Daniel-Christoph
    Yatabe, Yasushi
    Savchenko, Alexander
    Salcius, Jennifer
    Johng, Dorhyun
    Chen, Jing
    Montenegro, Giuliana
    Moehler, Markus
    JCO PRECISION ONCOLOGY, 2024, 8
  • [6] External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different
    Dodson, Andrew
    Parry, Suzanne
    Lissenberg-Witte, Birgit
    Haragan, Alex
    Allen, David
    O'Grady, Anthony
    McClean, Emma
    Hughes, Jamie
    Miller, Keith
    Thunnissen, Erik
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 138 - 145
  • [7] Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
    Fujimoto, Daichi
    Yamashita, Daisuke
    Fukuoka, Junya
    Kitamura, Yuka
    Hosoya, Kazutaka
    Kawachi, Hayato
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Date, Naoki
    Sakanoue, Ichiro
    Hamakawa, Hiroshi
    Takahashi, Yutaka
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2018, 38 (12) : 6891 - 6895
  • [8] PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
    Dabbagh, Tamara Z.
    Sughayer, Maher A.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) : 462 - 466
  • [9] CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays
    Beck, Kyongmin S.
    Kim, Seung Joon
    Kang, Jin Hyoung
    Han, Dae Hee
    Jung, Jung Im
    Lee, Kyo Young
    THORACIC CANCER, 2019, 10 (07) : 1612 - 1618
  • [10] CT-Guided Transthoracic Needle Biopsy for Evaluation of PD-L1 Expression: Comparison of 22C3 and SP263 Assays
    Beck, K.
    Lee, K. Y.
    Hong, S. J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S399 - S400
12345